Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleIEEE Spectrum

IEEE Report Predicts Tech That Will Transform Lives

View original at spectrum.ieee.org

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The technology is seeing a fundamental shift in how it evolves.

    60% confidence
  • Academia, industry, governments, and professional associations should work together; industry should partner on training programs, revive apprenticeships in physical sciences, and treat AI infrastructure as a long-term strategic asset; governments should lead on policy and reintegration programs for workers displaced by AI.

    60% confidence
  • The report shifts the conversation to how these advances will intersect to shape human lives; trust, safety, and human connection must guide every major breakthrough in the decade ahead.

    60% confidence
  • Within two years, genetic engineering and gene therapy will be used in therapeutic areas.

    60% confidence
  • By 2028, genetic engineering and gene therapy will be used frequently to treat a variety of diseases, thanks to advances in AI.

    60% confidence
  • Lack of computing infrastructure and energy sources constrains the ability to scale AI, and AI growth will require reshaping the workforce.

    60% confidence
  • Semiconductor manufacturing using parts built in space and more affordable reusable rockets are on the near horizon; clean energy generation in space and commercialization of orbital garbage collection are technologies to watch in the next decade.

    60% confidence
  • Space is not lagging; it reflects the current state of maturity, and the space sector will become increasingly important in coming years.

    60% confidence
  • Within two to three years, energy storage will double in developed countries.

    60% confidence
  • Factory androids will use tactile and haptic feedback within two to five years, and bio-inspired skin, tissues, and sensors will advance in the same timeframe.

    60% confidence
  • Under the Jevons paradox, as AI chip efficiency improves organizations will run more hardware to build larger frontier models, and data centers will draw as much power as grids can supply, leaving no surplus.

    60% confidence
  • Progress must be measured by more than technology development and implementation speed; the success of the megatrends depends on ensuring innovation strengthens human well-being and public trust.

    60% confidence
  • The energy industry has been relatively dormant for years, with little breakthrough innovation since the times of Edison and Tesla; governments will have to rethink power generation to stay ahead of demand.

    60% confidence
  • Within five years, earlier disease diagnoses will move from the lab into day-to-day medical practice, and researchers will likely be able to manufacture simple synthetic proteins to perform specific jobs in the body.

    60% confidence
  • AI adoption isn't an all-or-nothing approach; businesses should decide when and how to apply it.

    60% confidence
  • Communications between humans and AI will shift from text-based commands to predominantly audio and video instructions within two to three years.

    60% confidence
  • AI is no longer operating in a vacuum; it is now deeply connected to energy, infrastructure, and physical systems.

    60% confidence
  • Smarter, more efficient robots will substantially cut energy consumption in the next two years.

    60% confidence
  • AI technology is advancing faster than any previous revolution, including industrial, electrical, and digital.

    60% confidence
  • Human-AI interaction has the shortest adoption horizon of the 30 scored technologies, at two to three years; physical AI has the biggest chance of technical advancement of any megatrend in the next four years.

    60% confidence
  • Personalized medicine was scored the highest-impact technology at 4.93 out of 5.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com